Lexapro Patent Upheld On Appeal

Law360, New York (September 5, 2007, 12:00 AM EDT) -- A federal appeals court panel has upheld both the validity of Forest Laboratories Inc.’s patent on the blockbuster antidepressant drug Lexapro and an injunction thwarting Ivax Pharmaceuticals Corp.’s plans to market a generic.

The U.S. Court of Appeals for the Federal Circuit ruled Wednesday that the lower court correctly rejected Ivax's argument that the patent was anticipated, obvious and impermissibly broadened upon re-issue.

“We agree with Forest that the district court’s factual findings ... are not clearly erroneous, and, based upon those findings, we find no...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.